Aarti Pharmalabs Board Approves FY26 Audited Results, Recommends Rs. 2 Dividend
Aarti Pharmalabs Limited's Board approved audited standalone and consolidated financial results for FY26. The company reported a standalone net profit of ₹17,620.20 lakhs and consolidated net profit of ₹17,470.73 lakhs for the full year. A final dividend of ₹2 per equity share was recommended. Sachin Patil and Rajendra Pagare were appointed as Senior Management.
The approval of financial results and dividend recommendation are significant for shareholders. The designation of new senior management personnel also contributes to the company's operational and strategic direction, impacting its future performance.
The announcement includes the approval of audited financial results and the recommendation of a final dividend, which are generally positive indicators for investors.
Aarti Pharmalabs Limited announced the outcome of its Board Meeting held on May 25, 2026. The Board approved the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026, both on a standalone and consolidated basis.
Additionally, the Board recommended a Final Dividend of ₹2 per equity share (40% on face value of ₹5) for the Financial Year ended March 31, 2026, subject to shareholder approval at the upcoming Annual General Meeting. The company also re-appointed Smt. Ketki D. Visariya as the Cost Auditor and Manish Modi & Associates as the Internal Auditor for the Financial Year 2026-27. Mr. Sachin Patil (Head - Exports) and Mr. Rajendra Pagare (Head - Operations & Compliance) were designated as Senior Management Personnel, effective May 25, 2026.
The financial results for the quarter ended March 31, 2026, showed standalone net profit of ₹6,203.07 lakhs and consolidated net profit of ₹6,112.41 lakhs. For the full financial year ended March 31, 2026, standalone net profit was ₹17,620.20 lakhs and consolidated net profit was ₹17,470.73 lakhs.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.